Clinic Roundup

• Bio-Path Holdings Inc., of Houston, completed treatment of the first dosage cohort in the firm's Phase I trial of BP-100-1.01 (liposomal Grb-2), in development for systemic treatment of blood cancers such as acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome.